Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials
- 1 November 2015
- journal article
- Published by Elsevier in The Lancet Haematology
- Vol. 2 (11) , e492-e502
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Cardiovascular Disease After Hodgkin Lymphoma TreatmentJAMA Internal Medicine, 2015
- Late Morbidity and Mortality in Patients with Hodgkin's Lymphoma Treated During AdulthoodJNCI: Journal of the National Cancer Institute, 2015
- Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialThe Lancet, 2012
- Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 TrialJournal of Clinical Oncology, 2010
- Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's LymphomaNew England Journal of Medicine, 2010
- Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort StudyJNCI: Journal of the National Cancer Institute, 2007
- Late cardiotoxicity after treatment for Hodgkin lymphomaBlood, 2006
- Valvular Dysfunction and Carotid, Subclavian, and Coronary Artery Disease in Survivors of Hodgkin Lymphoma Treated With Radiation TherapyJAMA, 2003
- Involved-Field Radiotherapy for Advanced Hodgkin's LymphomaNew England Journal of Medicine, 2003